ACS Applied Materials & Interfaces,
Journal Year:
2023,
Volume and Issue:
15(37), P. 43359 - 43373
Published: Sept. 6, 2023
Antibody
drug
conjugates
(ADCs)
have
shown
promise
to
be
the
mainstream
chemotherapeutics
for
advanced
HER2-positive
cancers,
yet
issues
of
poor
delivery
efficiency,
limited
chemotherapeutic
effects,
severe
immune
responses,
and
resistance
remain
addressed
before
clinical
applications
ADCs.
The
DNA
aptamer-guided
(ApDCs)
are
receiving
growing
attention
specific
tumors
due
their
excellent
tumor
affinity
low
cost.
Therefore,
developing
a
multivalent
ApDC
nanomedicine
by
combining
anti-HER2
aptamer
(HApt),
tetrahedral
framework
nucleic
acid
(tFNA),
deruxtecan
(Dxd)
together
form
HApt-tFNA@Dxd
might
help
address
these
concerns.
In
this
study,
HER2-targeted
modified
tetrahedron
(HApt-tFNA)
was
employed
as
system
delivery,
adoption
tFNA
could
effectively
enlarge
drug-loading
rate
compared
ApDCs
previously
reported.
Compared
with
free
Dxd
tFNA@Dxd,
showed
better
structural
stability,
targeted
cytotoxicity
gastric
cancer,
increased
tissue
aggregation
ability
in
tumors.
These
features
superiorities
make
promising
medicine
Our
work
developed
new
targeting
nanomaterials
agents,
which
represents
critical
advance
toward
novel
DNA-based
promoting
potential
cancer
therapy.
Materials Today Bio,
Journal Year:
2025,
Volume and Issue:
31, P. 101534 - 101534
Published: Jan. 29, 2025
The
treatment
and
management
of
kidney
diseases
pose
a
significant
global
burden.
Due
to
the
presence
blood
circulation
barriers
glomerular
filtration
barriers,
drug
therapy
for
faces
challenges
such
as
poor
renal
targeting,
short
half-life,
severe
systemic
side
effects,
severely
hindering
therapeutic
progress.
Therefore,
research
development
kidney-targeted
agents
is
great
clinical
significance.
In
recent
years,
application
nanotechnology
in
field
nephrology
has
shown
potential
revolutionizing
diagnosis
diseases.
Carefully
designed
nanomaterials
can
exhibit
optimal
biological
characteristics,
influencing
various
aspects
circulation,
retention,
excretion.
Rationally
designing
modifying
based
on
anatomical
structure
pathophysiological
environment
achieve
highly
specific
or
nanodrug
delivery
systems
both
feasible
promising.
Based
targeted
diseases,
this
review
discusses
advantages
limitations
current
nanomedicine
summarizes
active/passive
targeting
strategies,
order
further
promote
through
preliminary
summary
previous
studies
future
prospects.
ACS Nano,
Journal Year:
2023,
Volume and Issue:
17(22), P. 22334 - 22354
Published: Oct. 2, 2023
As
a
major
late
complication
of
diabetes,
diabetic
peripheral
neuropathy
(DPN)
is
the
primary
reason
for
amputation.
Nevertheless,
there
are
no
wonder
drugs
available.
Regulating
dysfunctional
mitochondria
key
therapeutic
target
DPN.
Resveratrol
(RSV)
widely
proven
to
guard
mitochondria,
yet
unsatisfactory
bioavailability
restricts
its
clinical
application.
Tetrahedral
framework
nucleic
acids
(tFNAs)
promising
carriers
due
their
excellent
cell
entrance
efficiency,
biological
safety,
and
structure
editability.
Here,
RSV
was
intercalated
into
tFNAs
form
tFNAs-RSV
complexes.
achieved
enhanced
stability,
bioavailability,
biocompatibility
compared
with
alone.
With
treatment,
reactive
oxygen
species
(ROS)
production
minimized
reductases
were
activated
in
an
vitro
model
Besides,
respiratory
function
adenosine
triphosphate
(ATP)
enhanced.
also
exhibited
favorable
effects
on
sensory
dysfunction,
neurovascular
deterioration,
demyelination,
neuroapoptosis
DPN
mice.
Metabolomics
analysis
revealed
that
redox
regulation
energy
metabolism
two
principal
mechanisms
impacted
during
process.
Comprehensive
inspections
indicated
inhibited
nitrosation
oxidation
reductase
chain.
In
sum,
served
as
mitochondrial
nanoguard
(mito-guard),
representing
viable
drilling
drug
development
ACS Applied Materials & Interfaces,
Journal Year:
2023,
Volume and Issue:
15(37), P. 43359 - 43373
Published: Sept. 6, 2023
Antibody
drug
conjugates
(ADCs)
have
shown
promise
to
be
the
mainstream
chemotherapeutics
for
advanced
HER2-positive
cancers,
yet
issues
of
poor
delivery
efficiency,
limited
chemotherapeutic
effects,
severe
immune
responses,
and
resistance
remain
addressed
before
clinical
applications
ADCs.
The
DNA
aptamer-guided
(ApDCs)
are
receiving
growing
attention
specific
tumors
due
their
excellent
tumor
affinity
low
cost.
Therefore,
developing
a
multivalent
ApDC
nanomedicine
by
combining
anti-HER2
aptamer
(HApt),
tetrahedral
framework
nucleic
acid
(tFNA),
deruxtecan
(Dxd)
together
form
HApt-tFNA@Dxd
might
help
address
these
concerns.
In
this
study,
HER2-targeted
modified
tetrahedron
(HApt-tFNA)
was
employed
as
system
delivery,
adoption
tFNA
could
effectively
enlarge
drug-loading
rate
compared
ApDCs
previously
reported.
Compared
with
free
Dxd
tFNA@Dxd,
showed
better
structural
stability,
targeted
cytotoxicity
gastric
cancer,
increased
tissue
aggregation
ability
in
tumors.
These
features
superiorities
make
promising
medicine
Our
work
developed
new
targeting
nanomaterials
agents,
which
represents
critical
advance
toward
novel
DNA-based
promoting
potential
cancer
therapy.
